The cell proliferation antigen Ki-67 organises heterochromatin

  1. Michal Sobecki
  2. Karim Mrouj
  3. Alain Camasses
  4. Nikolaos Parisis
  5. Emilien Nicolas
  6. David Llères
  7. François Gerbe
  8. Susana Prieto
  9. Liliana Krasinska
  10. Alexandre David
  11. Manuel Eguren
  12. Marie-Christine Birling
  13. Serge Urbach
  14. Sonia Hem
  15. Jérôme Déjardin
  16. Marcos Malumbres
  17. Philippe Jay
  18. Vjekoslav Dulic
  19. Denis LJ Lafontaine
  20. Robert P Feil
  21. Daniel Fisher  Is a corresponding author
  1. Institute for Integrative Biology of the Cell, Université Paris Sud, France
  2. Montpellier Institute of Molecular Genetics, France
  3. Université Libre de Bruxelles, Belgium
  4. University of Montpellier, France
  5. Spanish National Cancer Research Centre, Spain
  6. Mouse Clinical Institute, France
  7. SupAgro, France

Abstract

Antigen Ki-67 is a nuclear protein expressed in proliferating mammalian cells. It is widely used in cancer histopathology but its functions remain unclear. Here, we show that Ki-67 controls heterochromatin organisation. Altering Ki-67 expression levels did not significantly affect cell proliferation in vivo. Ki-67 mutant mice developed normally and cells lacking Ki-67 proliferated efficiently. Conversely, upregulation of Ki-67 expression in differentiated tissues did not prevent cell cycle arrest. Ki-67 interactors included proteins involved in nucleolar processes and chromatin regulators. Ki-67 depletion disrupted nucleologenesis but did not inhibit pre-rRNA processing. In contrast, it altered gene expression. Ki-67 silencing also had wide-ranging effects on chromatin organisation, disrupting heterochromatin compaction and long-range genomic interactions. Trimethylation of histone H3K9 and H4K20 was relocalised within the nucleus. Finally, overexpression of human or Xenopus Ki-67 induced ectopic heterochromatin formation. Altogether, our results suggest that Ki-67 expression in proliferating cells spatially organises heterochromatin, thereby controlling gene expression.

Article and author information

Author details

  1. Michal Sobecki

    Department of Genome Biology, Institute for Integrative Biology of the Cell, Université Paris Sud, Gif-sur-Yvette, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Karim Mrouj

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Alain Camasses

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Nikolaos Parisis

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Emilien Nicolas

    RNA Molecular Biology, Fonds de la Recherche Nationale, Université Libre de Bruxelles, Charleroi-Gosselies, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  6. David Llères

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  7. François Gerbe

    Faculty of Sciences, University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Susana Prieto

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Liliana Krasinska

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Alexandre David

    Faculty of Sciences, University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Manuel Eguren

    Spanish National Cancer Research Centre, Madrid, Spain
    Competing interests
    The authors declare that no competing interests exist.
  12. Marie-Christine Birling

    Mouse Clinical Institute, Illkirch-Graffenstaden, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Serge Urbach

    Faculty of Sciences, University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Sonia Hem

    Mass Spectrometry Platform MSPP, SupAgro, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Jérôme Déjardin

    Faculty of Sciences, University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Marcos Malumbres

    Spanish National Cancer Research Centre, Madrid, Spain
    Competing interests
    The authors declare that no competing interests exist.
  17. Philippe Jay

    Faculty of Sciences, University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  18. Vjekoslav Dulic

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Denis LJ Lafontaine

    RNA Molecular Biology, Fonds de la Recherche Nationale, Université Libre de Bruxelles, Charleroi-Gosselies, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  20. Robert P Feil

    Montpellier Institute of Molecular Genetics, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  21. Daniel Fisher

    Montpellier Institute of Molecular Genetics, Montpellier, France
    For correspondence
    daniel.fisher@igmm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Fiona M Watt, King's College London, United Kingdom

Ethics

Animal experimentation: All animal experiments were performed in accordance with international ethics standards and were subjected to approval by the Animal Experimentation Ethics Committee of Languedoc Roussillon and the Ministry for Higher Education and Research

Version history

  1. Received: December 21, 2015
  2. Accepted: March 6, 2016
  3. Accepted Manuscript published: March 7, 2016 (version 1)
  4. Version of Record published: April 13, 2016 (version 2)

Copyright

© 2016, Sobecki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 15,477
    views
  • 2,066
    downloads
  • 241
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Michal Sobecki
  2. Karim Mrouj
  3. Alain Camasses
  4. Nikolaos Parisis
  5. Emilien Nicolas
  6. David Llères
  7. François Gerbe
  8. Susana Prieto
  9. Liliana Krasinska
  10. Alexandre David
  11. Manuel Eguren
  12. Marie-Christine Birling
  13. Serge Urbach
  14. Sonia Hem
  15. Jérôme Déjardin
  16. Marcos Malumbres
  17. Philippe Jay
  18. Vjekoslav Dulic
  19. Denis LJ Lafontaine
  20. Robert P Feil
  21. Daniel Fisher
(2016)
The cell proliferation antigen Ki-67 organises heterochromatin
eLife 5:e13722.
https://doi.org/10.7554/eLife.13722

Share this article

https://doi.org/10.7554/eLife.13722

Further reading

    1. Cancer Biology
    2. Cell Biology
    Camille Dantzer, Justine Vaché ... Violaine Moreau
    Research Article

    Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which oncogenic ß-catenin affects immune surveillance remain unclear. Herein, we highlighted the involvement of ß-catenin in the regulation of the exosomal pathway and, by extension, in immune/cancer cell communication in hepatocellular carcinoma (HCC). We showed that mutated ß-catenin represses expression of SDC4 and RAB27A, two main actors in exosome biogenesis, in both liver cancer cell lines and HCC patient samples. Using nanoparticle tracking analysis and live-cell imaging, we further demonstrated that activated ß-catenin represses exosome release. Then, we demonstrated in 3D spheroid models that activation of β-catenin promotes a decrease in immune cell infiltration through a defect in exosome secretion. Taken together, our results provide the first evidence that oncogenic ß-catenin plays a key role in exosome biogenesis. Our study gives new insight into the impact of ß-catenin mutations on tumor microenvironment remodeling, which could lead to the development of new strategies to enhance immunotherapeutic response.

    1. Cell Biology
    Zhongyun Xie, Yongping Chai ... Wei Li
    Research Article

    Asymmetric cell divisions (ACDs) generate two daughter cells with identical genetic information but distinct cell fates through epigenetic mechanisms. However, the process of partitioning different epigenetic information into daughter cells remains unclear. Here, we demonstrate that the nucleosome remodeling and deacetylase (NuRD) complex is asymmetrically segregated into the surviving daughter cell rather than the apoptotic one during ACDs in Caenorhabditis elegans. The absence of NuRD triggers apoptosis via the EGL-1-CED-9-CED-4-CED-3 pathway, while an ectopic gain of NuRD enables apoptotic daughter cells to survive. We identify the vacuolar H+–adenosine triphosphatase (V-ATPase) complex as a crucial regulator of NuRD’s asymmetric segregation. V-ATPase interacts with NuRD and is asymmetrically segregated into the surviving daughter cell. Inhibition of V-ATPase disrupts cytosolic pH asymmetry and NuRD asymmetry. We suggest that asymmetric segregation of V-ATPase may cause distinct acidification levels in the two daughter cells, enabling asymmetric epigenetic inheritance that specifies their respective life-versus-death fates.